Sign in
WithdrawnNo phase

Safety and Tolerability of a Novel Implantable Neurostimulator for Ameliorate Erectile Function on Spinal Cord Injured Patients

Key facts

Who runs it
Assistance Publique - Hôpitaux de Paris
Where
France1 site in 1 countryChoose a country to see its sites
Trial code
Status
Withdrawn
Started
May 2024
Ended
Nov 2025
Type of study
Interventional
Treatments tested
  • Implantation of the caverStim device
Record updated
15 June 2025
Why it stopped
The company that supplies the Medical Device has withdrawn.

Who can take part

Age
18 years to 45 years
Sex
Men only
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 29 criteriaShow less

Who can take part

  • Subjects have to fulfill all of the following inclusion criteria before being included in the run-in phase:
  • Written informed consent obtained from the subject
  • Men between the age of 18 to 45 years old with supra sacral spinal cord injury and below T6 as the upper limit
  • Men with stable spinal cord injury, which occurred at least 6 months prior to study enrolment
  • Men with documented neurogenic overactive detrusor activity according to urodynamic testing in their files
  • Have a monogamous relationship with a female sexual partner (vaginal penetration required for several of the primary efficacy variables) for at least 6 months prior to screening
  • Men with an insufficient response to PDE5-Is and interested in treating erectile dysfunction
  • Ability to understand and follow study-related instructions; Subjects have to fulfill all of the following inclusion criteria before being included in the implantation phase:
  • At least 4 sexual intercourse attempts during the 4-week run-in phase with use of 100 mg sildenafil approximately 1 hour before attempting intercourse
  • IIEF-EF score < 17 at the end of the run-in phase
  • At least 50% of attempts at sexual intercourse during the run-in phase had been unsuccessful i.e. the following question in the SEP Diary had to be answered with "No":; "Did your erection last long enough for you to have successful intercourse?" (SEP3: success in maintenance of erection)

Who cannot take part

  • Patients contraindicated for surgery under general anesthesia
  • Patients having met the criteria for unstable angina within 6 months prior to Visit 1, history of myocardial infarction or coronary artery bypass graft surgery within 90 days prior to Visit 1, or percutaneous coronary intervention (eg, angioplasty or stent placement) within 90 days prior to Visit 1
  • Any evidence of congestive heart failure within 6 months prior to Visit 1
  • History of previous pelvic surgery or irradiation therapy
  • Prior surgery for an implantable penile prosthesis
  • Patient has participated in any drug or device trial in the last 4 weeks or plans to participate in any other drug or device study in the next 24 months
  • Patients with known allergies to any of the device material (Platinum/iridium, silicone, pellethane, titanium, polysulfone, polyurethane)
  • History of priapism or Lapeyronie's disease
  • Any supraventricular arrhythmia with an uncontrolled ventricular response (mean heart rate >100 bpm) at rest despite medical therapy, or any history of spontaneous or induced sustained ventricular tachycardia (heart rate >100 bpm for >=30 sec) despite medical therapy
  • A history of sudden cardiac death (arrest) despite medical therapy
  • Patients with diabetes mellitus
  • All exclusion criteria will be assessed before the 4-week run-in phase
  • The presence of any one of the following exclusion criteria will lead to exclusion of the subject:
  • Patients with spinal cord lesion at T6 or above
  • Inability to understand and to follow instructions on device use
  • Patients not interested in sexual activity
  • Patients currently participating in another clinical investigation
  • Any other characteristics that, per the investigator's judgment, may increase the patients risk or impair the study conduct and data collection; such as depression or abnormal behavior for example

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The main objective of the study is to assess the safety and tolerability of cavernous nerve electrical stimulation in patients with spinal cord injured (SCI) by assessing and measuring complications.

Read full original descriptionShow less

As the secondary objectives, despite the limited cohort size, this long-term study aims to obtain preliminary data on efficacy of cavernous nerve stimulation to improve erectile function for sexual intercourse, as well as to assess patient's satisfaction using:

* Objective assessment of the erectile response upon CaverSTIM activation with the RigiScan device. * Subjective assessment of the erectile function with validated questionnaires:

1. A 6-item self-report instrument assessing male erectile function (Erectile Function domain of the International Index of Erectile Function, IIEF-EF); 2. A log-diary five item questionnaire completed after each sexual attempt (Sexual Encounter Profile, SEP); 3. A self-reporting measure that scores erection hardness on a 4-point scale (Erection Hardness Score, EHS); 4. The Global Assessment Question (GAQ).

In addition, the study aims to refine the method of implantation (step-by-step delineation of all technical approaches for device implantation, including duration of surgical procedure, blood loss, methods to access the periprostatic region, tissue dissection, device placement and fixation) prior to planning for larger scale clinical investigation.

The group in the trial

  • Implantation of the caverStim deviceTreatment being tested

    Implantation of caverStim in SCI patients

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Safety and Tolerability of a Novel Implantable Neurostimulator for Ameliorate Erectile Function: a Pilot Study in Spinal Cord Injured Patients
Record updated
15 June 2025